MedTrace Logo

MRI for Non-Invasive Imaging in Neonates and Children

NCT02163681 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-04-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to develop rapid MRI techniques for imaging the lung with hyperpolarized helium-3 gas as an inhaled contrast agent. These techniques will be piloted in adults and older children before testing them in younger children and infants. The purpose is to enable imaging of non-sedated infants by imaging so fast as to freeze motion.

Conditions

  • Healthy
  • Cystic Fibrosis (CF)
  • Asthma
  • Bronchopulmonary Dysplasia (BPD)

Interventions

DRUG

Hyperpolarized Helium-3 MRI of the chest

hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.

Sponsors & Collaborators

  • Xemed LLC

    collaborator INDUSTRY

  • University of Virginia

    lead OTHER

Principal Investigators

  • Yun M Shim, MD · University of Virginia

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Months
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2018-06-30
Completion
2018-07-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02163681 on ClinicalTrials.gov